文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

乌干达HIV-1感染者多替拉韦耐药调查

HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该横断面调查利用2022年2–4月残留病毒载量样本,对接受含多替拉韦方案≥9个月且病毒未抑制(≥1000拷贝/mL)的儿童和成人进行HIV-1 pol基因型检测。

要点

  • 病毒未抑制且用多替拉韦≥9个月者中,多替拉韦耐药不常见但可检出。
  • 儿童中高水平多替拉韦耐药率6.6%,成人3.9%。
  • 需纵向结局数据评估依从性咨询能否改善病毒未抑制者预后。

核心结论

  • 多替拉韦耐药在暴露≥9个月且病毒未抑制的儿童和成人中不常见但存在。

研究设计与样本

  • 横断面调查,使用2022年2–4月常规病毒载量监测残留样本。
  • 随机选取857份样本(成人457份、儿童400份)进行HIVDR检测。
  • 纳入接受含多替拉韦方案≥9个月且病毒载量≥1000拷贝/mL的儿童和成人。

主要发现

  • 成人多替拉韦中高水平耐药率为3.9%(95%CI 0.7–7.1)。
  • 儿童多替拉韦中高水平耐药率为6.6%(95%CI 3.5–9.6)。

关键数值与推荐

  • 病毒未抑制定义为病毒载量≥1000拷贝/mL。
  • 暴露于含多替拉韦方案至少9个月。
  • 使用Stanford HIVDR数据库判定耐药。

临床怎么用

  • 对含多替拉韦方案治疗≥9个月且病毒未抑制者,应考虑多替拉韦耐药检测。
  • 儿童病毒未抑制者多替拉韦耐药率较高,需关注其依从性管理与耐药监测。

局限性

  • 仅59.6%样本成功整合酶区基因型检测。
  • 横断面设计,缺乏纵向结局数据。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Uganda adopted dolutegravir as its preferred HIV treatment regimen in the national guidelines for treatment of HIV and AIDS in 2018. We conducted a survey to estimate dolutegravir resistance 4 years post-dolutegravir introduction in routine clinical settings. This was a cross-sectional survey to estimate the prevalence of HIV drug resistance (HIVDR) to dolutegravir among children and adults with viral non-suppression (VNS; ≥1000 copies/mL) receiving dolutegravir-based antiretroviral therapy for at least 9 months. METHODS: We used remnant specimens from routine viral load monitoring stored at Central Public Health Laboratories during February-April 2022. Genotyping of the protease, reverse transcriptase and integrase regions of the HIV-1 pol gene was done using Thermo Fisher® kits and analysed using the Stanford HIVDR database. Weighted prevalences of HIVDR with 95% confidence intervals (CI) were estimated for adults (≥15 years) and children (0-14 years). RESULTS: We randomly selected 857 specimens including 457 from adults and 400 from children for HIVDR testing from 3578 eligible specimens collected during February-April 2022. Five hundred and eleven (59.6%) were successfully genotyped in the integrase region. Intermediate- to high-level dolutegravir HIVDR prevalence was 3.9% (CI: 0.7, 7.1) for adults and 6.6% (CI: 3.5, 9.6) for children. CONCLUSION: HIVDR to dolutegravir was uncommon but present among both children and adults with VNS after 9 months or more of exposure to dolutegravir. Additional longitudinal outcomes data are needed to determine if adherence counselling for patients with VNS on dolutegravir regimens might improve outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Watera C, Da Silva JF, Namayanja G, et al. HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022. J Antimicrob Chemother. 2025. PMID: 40488412. doi:10.1093/jac/dkaf180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。